Medtronic PLC

NYSE MDT

Download Data

Medtronic PLC Operating Expense Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending April 30, 2024: -2.14%

Medtronic PLC Operating Expense Ratio 5 year CAGR is -2.14% for the Trailing 12 Months (TTM) ending April 30, 2024, a -908.72% change year over year. The operating expense ratio represents the proportion of a company's operating expenses to its revenue. It is calculated by dividing the operating expenses by the revenue. This ratio provides insights into the efficiency of a company's cost structure and its ability to control operating expenses relative to its revenue generation. A lower ratio indicates higher operational efficiency and cost management, while a higher ratio suggests higher operating expenses relative to revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Medtronic PLC Operating Expense Ratio for the Trailing 12 Months (TTM) ending April 30, 2023 was 48.17%, a -3.31% change year over year.
  • Medtronic PLC Operating Expense Ratio for the Trailing 12 Months (TTM) ending April 30, 2022 was 49.81%, a -1.10% change year over year.
  • Medtronic PLC Operating Expense Ratio for the Trailing 12 Months (TTM) ending April 30, 2021 was 50.37%, a -1.55% change year over year.
  • Medtronic PLC Operating Expense Ratio for the Trailing 12 Months (TTM) ending April 30, 2020 was 51.16%, a 3.09% change year over year.
NYSE: MDT

Medtronic PLC

CEO Mr. Geoffrey Straub Martha
IPO Date Jan. 13, 1978
Location Ireland
Headquarters 20 On Hatch, Dublin, Ireland, 2
Employees 95,000
Sector Healthcare
Industry Medical devices
Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Similar companies

ABT

Abbott Laboratories

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email